Magazine Article | July 1, 2021

Is The Advent Of Decentralized Clinical Trials A Blessing Or A Curse?

Source: Life Science Leader

By John Illingworth

As the evolution of wearables, mHealth apps, and other technologies has minimized the need for patients to endure arduous in-person monitoring, decentralized clinical trials (DCTs) have been on the upswing. In the past year, necessity born of COVID-19 escalated DCTs’ use exponentially — and now that patients have begun to adapt, there is no going back. While sponsors, concerned about patient-centricity, are embracing the idea, sites are worried about implementation. They are asking: “Can we really do this?”

VIEW THE MAGAZINE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Life Science Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: